Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
125.875(c) 122.625(c) 123.625(c) 120.5(c) 123.875(c) Last
27 947 394 599 43 410 23 148 1 329 Volume
+2.34% -2.58% +0.82% -2.53% +2.80% Change
More quotes
Financials ($)
Sales 2017 1,63 M
EBIT 2017 -120 M
Net income 2017 -97,2 M
Finance 2017 171 M
Yield 2017 -
Sales 2018 2,85 M
EBIT 2018 -130 M
Net income 2018 -101 M
Finance 2018 110 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 134x
EV / Sales2018 97,6x
Capitalization 388 M
More Financials
Company
PureTech Health Plc is a cross-disciplinary biopharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune.It operates through the following segments: Growth Stage Businesses; Project Phase Businesses; and... 
More about the company
Surperformance© ratings of Puretech Health PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PURETECH HEALTH PLC
11/09 PURETECH HEALTH : Vedanta Biosciences Awarded Up To $5.4 Million from CARB-X to ..
11/09 PURETECH HEALTH : to Present at Jefferies 2017 Healthcare Conference in London
11/03 PURETECH HEALTH : Vedanta Biosciences Awarded $5.4 Million Grant from Combating ..
11/03 VEDANTA BIOSCIENCES : Awarded Up To $5.4 Million from CARB-X to Accelerate Devel..
11/01 PURETECH HEALTH : Vedanta Licenses Microbiome-Derived Immuno-Oncology Product Ca..
11/01 VEDANTA BIOSCIENCES : to Advance Cancer Immunotherapy Candidates Based on Microb..
09/28 PURETECH HEALTH : Notes U.S. Patent Issuance Broadly Covering Methods of Assessi..
09/25 GELESIS : 100 Achieves Significant Weight Loss with Excellent Safety Profile in ..
09/25 PURETECH HEALTH : Gelesis Reports Significant Weight Loss with Excellent Safety ..
09/20 PURETECH HEALTH : Notes US Patent Issuance Broadly Covering Methods of Assessing..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
Chart PURETECH HEALTH PLC
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 3,16 $
Spread / Average Target 93%
EPS Revisions
Managers
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Eric Elenko Chief-Research & Strategy
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC5.09%388
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538